COVID-X finanzierà un progetto synbrAIn sulle immagini radiografiche

COVID-X to Fund a New synbrAIn Project

  • Post author:
  • Post category:News

As part of its ongoing commitment to innovation, the synbrAIn team has launched AIDE-X, an acronym for Artificial Intelligence for Early Detection of Lung Diseases from Chest X-ray Images.

AIDE-X is a research project aimed at supporting pneumonia detection while also identifying its underlying causes, distinguishing COVID-19-related pneumonia from other types. The solution is designed to analyze chest X-ray images, enabling healthcare professionals to compare them with similar cases.

Key Benefits of AIDE-X

This innovative approach provides several advantages to its end users:

  • It relies on X-ray imaging instead of CT scans, reducing radiation exposure for patients;
  • It offers lower costs for both patients and healthcare systems;
  • X-ray machines are more accessible and widely available than CT scanners, making it easier to implement this solution in various medical settings.

AIDE-X Selected by COVID-X for Funding

For these reasons, AIDE-X, led by synbrAIn as the principal investigator, was among the few projects selected by the scientific committee of the COVID-X program. COVID-X is a European innovation initiative that provides funding and an acceleration program to startups and companies working on AI-driven solutions to combat COVID-19 and save lives.

Supported by the European Commission, COVID-X is part of the EU’s pandemic response plan, leveraging data-driven technologies to fight COVID-19.

Through two Open Calls, COVID-X selected 13 projects from 73 applications, granting funding and mentorship to approximately 30 companies across 8 European countries.

Strategic Support for AIDE-X

With COVID-X’s support, synbrAIn will receive guidance on ethical compliance for clinical data management and the opportunity to validate AIDE-X in clinical settings at one of COVID-X’s pilot sites in Italy, Spain, and Sweden.

The clinical partner for AIDE-X will be Istituto Clinico Humanitas, which will provide X-ray images and corresponding diagnoses to help train and validate synbrAIn’s machine learning models.

Additionally, business consultants will assist participating companies in developing go-to-market strategies. One of COVID-X’s key goals is to help companies transition to a higher level of technological maturity using the Technology Readiness Level (TRL) framework.

Advancing AI in Healthcare with COVID-X

TRL is a widely adopted methodology used by international organizations to assess the maturity of new technologies on a nine-level scale, ranging from TRL 1 (basic research) to TRL 9 (fully operational and market-ready technology).

COVID-X aims to help companies already at TRL 7 or 8 move to TRL 9, providing expert guidance to accelerate this transition.

synbrAIn was selected for this initiative thanks to its continuous advancements in AI-driven healthcare solutions, as demonstrated by previous collaborations, including the development of MS humanAId. The company’s technology readiness was assessed at TRL 8, making it an ideal candidate for COVID-X’s final acceleration phase.

Joining COVID-X represents a major achievement for synbrAIn, recognizing its dedication to AI-driven healthcare innovation while also providing significant financial support for its growth. This opportunity is particularly meaningful given AIDE-X’s alignment with synbrAIn’s mission: to develop innovative solutions that foster human-machine collaboration.